Building 4
Suite 200 3000 El Camino Real
Palo Alto, CA 94306
United States
650 507 0669
https://180lifesciences.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 4
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Executive Chairman | 168,75k | N/A | 1948 |
Dr. James N. Woody M.D., Ph.D. | CEO & Director | 617,77k | N/A | 1942 |
Mr. Ozan Pamir C.F.A. | CFO & Secretary | 410,24k | N/A | 1992 |
Dr. Jonathan B. Rothbard Ph.D. | Chief Scientific Officer | 260,34k | N/A | 1953 |
Prof. Jagdeep Nanchahal | Co-Founder & Chairman of Clinical Advisory Board | N/A | N/A | N/A |
Mr. Jason Assad | Director of IR | N/A | N/A | N/A |
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
180 Life Sciences Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.